Advertisement

Thyroid-Imipramine Interaction: Clinical Results and Basic Mechanism

  • Arthur J. PrangeJr.
  • Ian C. Wilson
  • Angelina E. Knox
  • Thomas K. McClane
  • George R. Breese
  • Billy R. Martin
  • Lacoe B. Alltop
  • Morris A. Lipton
Part of the Advances in Behavioral Biology book series (ABBI, volume 1)

Abstract

In recent years, our group has drawn attention to a new phenomenon that can be described quite simply. Patients with primary depression recover more quickly if, to a usual regimen of imipramine, one adds a small dose of thyroid hormone, L-triiodothyronine (T3) (Prange et al. 1968; Prange et al. 1969; Wilson et al. 1970; Prange et al. 1970). Since then we have worked in two directions in both our clinic and our laboratory. We have explored the clinical dimensions of our finding and have tried simultaneously to elucidate the mechanisms that underlie it. This paper will outline the phenomenon briefly and then discuss one of our attempts to understand it. In another paper (Prange, Wilson, and Lipton, in preparation) we shall publish data that verify the following qualifications:
  1. 1.

    When imipramine alone is given, men respond much faster than women.

     
  2. 2.

    When T3 is added to imipramine, women benefit enormously and men benefit little, if at all.

     
  3. 3.

    Whether patients are retarded or agitated has no influence on the T3 phenomenon, though it has some influence on basic response to imipramine.

     

Keywords

Thyroid Hormone Normal Woman Placebo Patient Depressed Woman Vanillylmandelic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ashcroft, G. W.; Crawford, T. B. B.; Eccleston, D.; Sharman, D. F.; MacDougall, E. J.; Stanton, J. B.; and Binns, J. K. 1966. 5-Hydroxyindole compounds in the cerebrospinal fluid of,patients with psychiatric or neurological disease. Lancet 2:1049.PubMedCrossRefGoogle Scholar
  2. Bourne, H. R.; Bunney, W. E., Jr.; Colburn, R. W.; Davis, J. M.; Davis, J. N.; Shaw, D. M.; and Coppen, A. J. 1968. Noradrenaline, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid in hindbrains of suicidal patients. Lancet 2:805.PubMedCrossRefGoogle Scholar
  3. Bunney, W. E.; Davis, J. M.; Weil-Malherbe, H.; and Smith, E. R. B. 1967. Biochemical changes in psychotic depression: High norepi-nephrine levels in psychotic versus neurotic depression. Arch. Gen. Psychiat. 16:448.PubMedCrossRefGoogle Scholar
  4. Cohn, C. K.; Dunner, D. L.; and Axelrod, J. 1971. Reduced cat-echol-O-methyltransferase activity in red blood cells of women with primary affective disorder. Science 170:1323.CrossRefGoogle Scholar
  5. Coppen, A. 1967. The biochemistry of affective disorders. Brit. J. Psychiat. 113:1237.PubMedCrossRefGoogle Scholar
  6. Coppen, A.; Shaw, D. M.; Malleson, A.; Eccleston, E.; and Gundy, G. 1965. Tryptamine metabolism in depression. Brit. J. Psychiat. 111:993.PubMedCrossRefGoogle Scholar
  7. Dairman, W. R.; Gordon, R.; Spector, S.; Sjoerdsma, A.; and Udenfriend, S. 1968. Effect of alpha-blockers on catecholamine biosynthesis. Fed. Proc. 27:240..Google Scholar
  8. Dencker, S. J.; Malm, U.; Roos, B. E.; and Werdinius, B. 1966. Acid monoamine metabolites of cerebrospinal fluid in mental depression and mania. J. Neurochem. 13:1545.PubMedCrossRefGoogle Scholar
  9. Earle, B. V. 1970. Thyroid hormone and tricyclic antidepressants in resistant depressions. Amer. J. Psychiat. 126:143.Google Scholar
  10. Goetsch, E. 1918. Newer methods in the diagnosis of thyroid disorders: pathological and clinical. New York J. Med., 18:259.Google Scholar
  11. Hamilton, M. 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiat. 23:56.PubMedCrossRefGoogle Scholar
  12. Lipton, M. A.; Prange, A. J., Jr.; Dairman, W.; and Udenfriend, S. 1968. Increased rate of norepinephrine biosynthesis in hypothy-roid rats. Fed. Proc. Abstracts 27:399.Google Scholar
  13. Long, C. (ed.) 1968. Biochemist’s Handbook. Princeton, N. J.: D. Van Nostrand, p. 926.Google Scholar
  14. Maas, J. W.; Fawcett, J.; and Dekirmenjian, H. 1968. 3-Methoxy-4-hydroxy phenylglycol (MHPG) excretion in depressive states. Arch. Gen. Psychiat. 19:129.PubMedCrossRefGoogle Scholar
  15. Maas, J. W. Personal communication.Google Scholar
  16. McClane, T.; Wilson, I. C.; and Prange, A. J., Jr. The effects of imipramine and L-triiodothyronine on mental activity, thyroid state, and response to norepinephrine infusion in normal women. In preparation.Google Scholar
  17. McClure, D. J.; and Cleghorn, R. A. 1968. Suppression studies in affective disorders. Canad. Psychiat. Assoc. J. 13:477.Google Scholar
  18. Nybäck, H.; and Sedvall, G. 1968. Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine-C14 in brain. J. Pharmacol Exp. Ther. 162:294.PubMedGoogle Scholar
  19. Park, S.; Prange, A. J., Jr.; and Happy, J. The effects of altered thyroid state in phenothiazine response distribution and metabolism in the rat. In preparation.Google Scholar
  20. Prange, A. J., Jr.; and Lipton, M. A. 1962. Enhancement of imipra-mine mortality in hyperthyroid mice. Nature 196:588.PubMedCrossRefGoogle Scholar
  21. Prange, A. J., Jr.; Lipton, M. A.; and Love, G. N. 1963. Diminution of imipramine mortality in hypothyroid mice. Nature 197:1212.PubMedCrossRefGoogle Scholar
  22. Prange, A. J., Jr.; Lipton, M. A.; and Love, G. N. 1964. The effect of altered thyroid status on desmethylimipramine mortality in mice. Nature 204:1204.PubMedCrossRefGoogle Scholar
  23. Prange, A. J., Jr.; McCurdy, R. L.; and Cochrane, C. M. 1967. The systolic blood pressure response of depressed patients to infused norepinephrine. J. Psychiat. Res. 5:1.PubMedCrossRefGoogle Scholar
  24. Prange, A. J., Jr.; Wilson, I. C.; Rnox, A. E.; McClane, T. K.; and Lipton, M. A. 1970. Enhancement of imipramine by thyroid stimulating hormone: clinical and theoretical implications. Amer. J. Psychiat. 127:191.PubMedGoogle Scholar
  25. Prange, A. J., Jr.; Wilson, I. C.; and Lipton, M. A. In preparation.Google Scholar
  26. Prange, A. J., Jr.; Wilson, I. C.; Rabon, A. M.; and Lipton, M. A. 1968. Enhancement of imipramine by triiodothyronine in unselected depressed patients. Excerpta Medica International Congress Series. No. 180, p. 532.Google Scholar
  27. Prange, A. J., Jr.; Wilson, I. C.; Rabon, A. M.; and Lipton, M. A. 1969. Enhancement of imipramine antidepressant activity by thyroid hormone. Amer. J. Psychiat. 126:457.PubMedGoogle Scholar
  28. Rodnight, R. 1961. Body fluid indoles in mental illness. Int. Rev. Neurobiol. 3:251.CrossRefGoogle Scholar
  29. Rosenblatt, S.; Chanley, J. D.; and Leighton, W. P. 1969a. The investigation of adrenergic metabolism with 7H3-norepinephrine in psychiatric disorders—I. Temporal change in the distribution of urinary tritiated metabolites and the effects of drugs. J. Psychiat. Res. 6:307.PubMedCrossRefGoogle Scholar
  30. Rosenblatt, S.; Chanley, J. D.; and Leighton, W. P. 1969b. The investigation of adrenergic metabolism with 7H3-norepinephrine in psychiatric disorders—II. Temporal changes in the distribution of urinary tritiated metabolites in affective disorders. J. Psychiat. Res. 6:321.PubMedCrossRefGoogle Scholar
  31. Schildkraut, J. J.; Gordon, E. K.; and Durrell, J. 1965. Catechol-amine metabolism in affective disorders: I. Normetanephrine and VMA excretion in depressed patients treated with imipramine. J. Psychiat. Res. 3:213.PubMedCrossRefGoogle Scholar
  32. Sjoerdsma, A.; Oates, J. A.; Zaltman, P.; and Udenfriend, S. 1959. Identification and assay of urinary tryptamine: application as an index of monoamine oxidase inhibition in man. J. Pharmacol Exp. Ther. 126:217.PubMedGoogle Scholar
  33. Spencer, P. S. J.; and West, G. B. 1961. Sensitivity of the hyper-thyroid and hypothyroid mouse to histamine and 5-hydroxytryptamine. Brit. J. Pharmacol. 17:137.PubMedGoogle Scholar
  34. Taniguchi, K.; Kakimoto, Y.; and Armstrong, M. D. 1964. Quantitative determination of metanephrine and normetanephrine in urine. J. Lab. Clin. Med. 64.Google Scholar
  35. Toth, S.; and Csaba, B. 1966. The effect of thyroid gland on 5-hydroxytryptamine (5-HT) level of brain stem and blood in rabbits. Experientia 22:755.CrossRefGoogle Scholar
  36. Udenfriend, S.; Titus, E.; and Weissbach, H. 1955. The identification of 5-hydroxy-3-indoleacetic acid in normal urine and a method for its assay. J. Biol. Chem. 216:499.PubMedGoogle Scholar
  37. Wheatley, D. A comparative trial of amitryptyline with two dose levels of L-triiodothyronine in depressed outpatients. In preparation.Google Scholar
  38. Wilk, S.; Gitlow, S. E.; Clarke, D. D.; and Paley, D. H. 1967. Determination of urinary 3-methoxy-4-hydroxyphenylethylene glycol by gas-liquid chromatography and electron capture detection. Clin. Chim. Acta. 16:403.PubMedCrossRefGoogle Scholar
  39. Wilk, S.; Gitlow, S. E.; Mendlowitz, M.; Franklin, M. J.; Carr, H. E.; and Clarke, D. D. 1965. A quantitative assay for vanillylmandelic acid (VMA) by gas-liquid chromatography. Anal. Biochem. 13:544.PubMedCrossRefGoogle Scholar
  40. Williams, E. D. 1968. 5-Hydroxyindoles and the thyroid. Advances Pharmacol. 6:(suppl.)151.CrossRefGoogle Scholar
  41. Wilson, I. C.; Prange, A. J., Jr.; McClane, T. K.; Rabon, A. M.; and Lipton, M. A. 1970. Thyroid-hormone enhancement of imipramine in nonretarded depressions. New Eng. J. Med. 282:1063.PubMedCrossRefGoogle Scholar
  42. Wyatt R. J.; Portnoy, B.; Kupfer, D. J.; Snyder, F.; and Engleman, K. 1971. Resting plasma catecholamine concentrations in patients with depression and anxiety. Arch. Gen. Psychiat. 24:65.PubMedCrossRefGoogle Scholar
  43. Zung, W. W. K. 1970. A self-rating depression scale. Arch. Gen. Psychiat. 12:63.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1971

Authors and Affiliations

  • Arthur J. PrangeJr.
    • 1
  • Ian C. Wilson
    • 2
  • Angelina E. Knox
    • 3
  • Thomas K. McClane
    • 4
  • George R. Breese
    • 1
  • Billy R. Martin
    • 1
  • Lacoe B. Alltop
    • 2
  • Morris A. Lipton
    • 1
  1. 1.University of North Carolina School of MedicineChapel HillUSA
  2. 2.North Carolina Department of Mental HealthChapel HillUSA
  3. 3.Dorothea Dix HospitalReleighUSA
  4. 4.LakelandUSA

Personalised recommendations